[1]. Its efficacy is documented in cognitive disorders
and dementia, vertigo, cortical myoclonus, dyslexia, and sickle
cell anemia although the clinical application in these conditions
is not yet established. Piracetam has effects on the vascular
system by reduce erythrocyte adhesion to vascular endothelium,
hinder vasospasm and facilitate microcirculation Originally marketed by UCB Pharma in ***1, piracetam
was the first nootropic drug to modulate cognitive function without
causing sedation or stimulation . In the United States, it is not approved by the US Food and
Drug Administration for any medical use and it is not permitted to
be sold as a dietary supplement. In the UK, piracetam is prescribed
mainly for myoclonus, but is used off-label for other conditions
such as learning difficulties in children, memory loss or other
cognitive defects in the elderly, and sickle-cell vaso-occlusive
crises . Evidence to support
its use for many conditions is unclear.
